Spend by Cancer52 members and combined spend with NCRI partners was broken down into regional spend by the principal investigator…
Cancer52 Member spend
Spend by Cancer52 members looked at separately from NCRI partners. OverviewAnalysis of the data showed that Cancer52 members spent £23,674,012…
Cancer spend on rare and less common cancers compared to common cancers
Spend by research area in rare and less common cancers (NCRI and Cancer52 members combined) against spend in the most…
Reducing the risk of long-term heart problems later in life from cancer treatment – the role of proton beam therapy
Reducing the risk of long-term heart problems later in life from cancer treatment – the role of proton beam therapy…
NCRI welcomes partnership between the UK government and BioNTech
The UK Government and BioNTech today announced a partnership to develop immunology treatments. In response, NCRI Chair Fiona Driscoll has…
Combined spend on rare and less common cancers
Combining Cancer52 members with NCRI partners to provide a more complete picture of research spend in rare and less common…
Existing evidence on cancer research spend and burden
A look at published evidence examining the mortality and wider societal burden of cancer types. External factors that affect research…
Summary
An overview of key information from the analysis. 0 % of overall spend on site specific cancer research is on…
Methodology
A summary of the process to collate the data for this analysis, along with the classification systems used. To acquire…
Background
How the analysis was instigated, and information about the National Cancer Research Institute (NCRI) and Cancer52. The National Cancer Research…
NCRI Newsletter | November 2022
NCRI’s CTRad is currently inviting radiotherapy research ideas for open discussion and peer input prior to application to funding bodies…